Press Releases
Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn’s Disease
Loading...
End of content
No more pages to load
Agomab Therapeutics Selected as One of Fierce Biotech’s “Fierce 15” Companies of 2022
Agomab Raises Additional $40.5 Million Through Series B Extension Bringing Total Amount to $114 Million
Agomab to Present at 40th Annual J.P. Morgan Healthcare Conference and Announces Additional Upcoming Conference Participations in Q1
Loading...
End of content
No more pages to load
Agomab Expands Team with Reginald Brys as Head of Research and Maria Nichol as Head of IP
Agomab Therapeutics Completes Acquisition of Origo Biopharma
Agomab Therapeutics to Acquire Origo Biopharma
AgomAb Therapeutics Expands Senior Team with General Counsel and Head of Clinical Operations
AgomAb Announces Two Oral Presentations at the EASL Liver Congress 2021
AgomAb Therapeutics Raises $74 Million Series B to Advance Regenerative Pathway Modulators
Loading...
End of content
No more pages to load
AgomAb Therapeutics Closes Series A Extension Round with Additional Funding from Andera Partners
AgomAb Therapeutics Completes €21m Series A Financing
Loading...
End of content
No more pages to load
Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn’s Disease
Agomab Therapeutics Selected as One of Fierce Biotech’s “Fierce 15” Companies of 2022
Agomab Raises Additional $40.5 Million Through Series B Extension Bringing Total Amount to $114 Million
Agomab to Present at 40th Annual J.P. Morgan Healthcare Conference and Announces Additional Upcoming Conference Participations in Q1
Agomab Expands Team with Reginald Brys as Head of Research and Maria Nichol as Head of IP
Agomab Therapeutics Completes Acquisition of Origo Biopharma
Agomab Therapeutics to Acquire Origo Biopharma
AgomAb Therapeutics Expands Senior Team with General Counsel and Head of Clinical Operations
AgomAb Announces Two Oral Presentations at the EASL Liver Congress 2021
AgomAb Therapeutics Raises $74 Million Series B to Advance Regenerative Pathway Modulators
AgomAb Therapeutics Closes Series A Extension Round with Additional Funding from Andera Partners
AgomAb Therapeutics Completes €21m Series A Financing
Loading...
End of content
No more pages to load
Looking to connect with us?
April 6, 2023
Rotterdam, The Netherlands
Kempen Life Sciences Conference
April 25-26, 2023
Amsterdam, The Netherlands
J.P. Morgan CEO Forum
May 9, 2023
London, UK
Bio€quity Europe 2023
May 15-23, 2023
Dublin, Ireland
AgomAb in the News
Fierce Biotech – Fierce Biotech’s 2022 Fierce 15
FierceBiotech – AgomAb raises $74M to develop regenerative pathway modulators.